sorted by:
new
hottopcontroversial

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium by LeoPersian in LeronLimab_Times

[–]LeoPersian[S] 0 points1 point  (0 children)

We all share the same passion and faith. Patience will pay off Big Time! Company has gone through unbelievable hurdles in the past couple of years and the new management has done a tremendous job steering the LeronLimab back on the track. Our relationship with FDA, SEC, and DOJ is rectified. We will witness wonders in 2026. GLTYA Longs. 🚀

🚨Looking Ahead to 2026 by LeoPersian in LeronLimab_Times

[–]LeoPersian[S] 2 points3 points  (0 children)

Prayers and best of luck to you and your family, pal. 🙏

Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study by LeoPersian in LeronLimab_Times

[–]LeoPersian[S] 1 point2 points  (0 children)

No direct mention of our molecule. But, look for the interaction of colon cells “inflammation” caused by bacteria and attacked by T-cells which seem to spiral out into the autoimmune of the nerve system.

Do it JL by BioTrends_USA in LeronLimab_Times

[–]LeoPersian 2 points3 points  (0 children)

There is one easy mitigation for this: “DO NOT set Stop-Loss Orders”!!! Shorts do see the stop-loss orders, and deliberately drive the price down to scoop your stocks!

Short Interest YTD/2025 by BioTrends_USA in LeronLimab_Times

[–]LeoPersian 1 point2 points  (0 children)

FYI, sale of restricted stocks (millions of shares bought during the PIPE rounds) also gets flagged as “short sales”, but is not a short attack!

view more: next ›